• Login
    View Item 
    •   SU+ Home
    • Conferences / Workshops / Seminars +
    • Strathmore International Mathematics Conference
    • SIMC 2012
    • View Item
    •   SU+ Home
    • Conferences / Workshops / Seminars +
    • Strathmore International Mathematics Conference
    • SIMC 2012
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Stochastic modeling of HIV dynamics within an individual and its management

    Thumbnail
    View/Open
    Conference paper (312.2Kb)
    Author
    Mbogo, Rachel Waema
    Metadata
    Show full item record
    Abstract
    Mathematical models can facilitate the understanding of complex biomedical systems such as in HIV/AIDS. Untangling the dynamics between HIV and CD4+ cellular populations and molecular interactions can be used to investigate the effective points of interventions in the HIV life cycle. With that in mind, we will develop state transition systems dynamics and stochastic model that can be used to examine various alternatives for the control and treatment of HIV/AIDS, and also determine the cost of treating an HIV patient such that the expected lifetime or quality-adjusted lifetime of the patient is maximized. The AIDS epidemic is extremely dynamic; this dynamism orthogonally complicates interventions embraced for the management of the epidemic. This research is mostly motivated by the fact that eradication of the HIV virus is not attainable with the current available drugs and now the focus is not virus eradication but the management and control of the virus progression. We will develop and analyze Non-Homogeneous Semi-Markov Stochastic (NHSMS) Models of HIV biological process and compute internal transition probabilities. Specifically the models will target: the HIV internal dynamics in an infected person, defined by CD4+ levels and Viral load, and the disease control and management strategies put in place. Secondly we will use Non-Homogeneous Semi-Markov Reward (NHSMR) processes to determine the cost of treating an HIV patient, and lastly, we consider the revenue generated by such person (as well as the expert advice by such infected person into various projects) such that the Cost Benefit Analysis (CBA) can also be conducted.
    URI
    http://hdl.handle.net/11071/3527
    Collections
    • SIMC 2012 [18]

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of SU+Communities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV